SC
RVMD icon

Stephens Consulting’s Revolution Medicines RVMD Stock Holding History

Stephens Consulting’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$1.77K – 1836
2025
Q1 		$1.77K Buy
+50
New +$2.03K ﹤0.01% 471

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Stephens Consulting's RVMD Position: Q2 2025 in Review

Stephens Consulting sold out of Revolution Medicines (RVMD) in Q2 2025, closing a stake of 50 shares — an estimated $1.77K sold.

Stephens Consulting first reported a position in RVMD in Q1 2025 and held it in 1 quarter. The position peaked at $1.77K in Q1 2025. 307 funds tracked by Wall St. Rank hold RVMD as of Q2 2025.

  • Stephens Consulting reported no remaining Revolution Medicines position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 50 Revolution Medicines shares in Q2 2025, an estimated $1.77K.
  • Stephens Consulting first reported a position in Revolution Medicines in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Revolution Medicines position peaked at $1.77K in Q1 2025.
  • 307 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.